Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AntiRetroviral Therapy In Second-line: Investigating Tenofovir-lamivudine-dolutegravir (ARTIST): a Randomised Controlled Trial

NCT03991013 is registered in ClinicalTrials.gov with University of Cape Town as lead sponsor.

NCT NCT03991013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03991013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AntiRetroviral Therapy In Second-line: Investigating Tenofovir-lamivudine-dolutegravir (ARTIST): a Randomised Controlled Trial
Lead sponsor
University of Cape Town
Phase
Phase 2
Overall status
Completed
Start date
August 8, 2019
Completion date
October 27, 2022
Enrollment
192 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections